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S324 Poster Session IIby progressive localization of the BLI signal to the tumor site. The
accumulation of NK cells increased with increasing tumor size,
such that the BLI signal of NK cells from the tumor bed repre-
sented approximately 30% of the total animal BLI. Survival advan-
tage was not observed in animals receiving NK cells, regardless of
the administration of IL-2. The tumor microenvironment (TME)
contained a network of Treg cells as well as conventional and plas-
macytoid dendritic cells, most of which were donor bone-marrow
derived and were markedly increased when compared with control
tissues (Tregs 40% vs 8%, p5 0.0034; cDC 30% vs 6%, p5 0.02).
Donor NK cells reisolated from the tumor showed a trend to re-
duced activation by CD69 expression (3% compared with 24%
in normal spleen, p5 0.09), and similarly had impaired production
of interferon-gamma upon restimulation.
Conclusions: Adoptively transferred allogeneic NK cells home to
tumor, showing a striking and paradoxical accumulation with in-
creasing tumor size. These NK are de-activated, possibly due to ex-
posure to the immunosuppressive TME.474
SEQUENTIAL GENE EXPRESSION ANALYSIS DURING THE EARLY ALLOR-
EACTIVE PHENOMENA AFTER ALLOGENEIC BMT IDENTIFIES GENE SETS
AND PATHWAYS DIFFERENTIALLY EXPRESSED IN THE SKIN AND THE
BLOOD OF BMT RECIPIENTS: IMPLICATIONS FOR THE DISCOVERY OF
BIOMARKERS OF CUTANEOUS GVHD THAT ARE RELEVANT TO THE
TARGET ORGAN
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Our understanding of the alloreactive phenomena that follow
allogeneic BMT (alloBMT) and lead to GVHD in target organs
comes essentially from animal models. In humans, the use of tar-
get tissues has been largely limited to diagnostic purposes, while
the study of immunological pathways and biomarkers of GVHD
has been performed in peripheral blood (PB) or urine. Hence,
we decided to collect prospectively and in parallel skin biopsies
and PB samples before and after alloBMT in order to investigate
sequential changes in alloreactive phenomena and biomarkers that
are relevant to the skin as a target organ of GVHD. Sixty-five
adult recipients of alloBMT for hematological malignancies (38
male; age 49, 21-67; 38 reduced intensity; 40 related donor) had
PB and skin biopsies taken pretransplant and on days 0, +14-21,
+100 and at the start of GVHD. A high-throughput discovery-
driven strategy was carried out using Agilent Whole Genome Mi-
croarrays on RNA from PBMCs and snap-frozen skin extracted
with TRIZOL and amplified with RNA ampULSe. Gene expres-
sion data was analyzed using GSEA software (www.broadinstitu
te.org/gsea/index.jsp), GEPAS (www.gepas.org) and POMELO
(http://pomelo2.bioinfo.cnio.es/) web tools. Our initial analysis
presented here focuses on early kinetics of gene expression in
skin and PB after alloBMT. Comparative profiles between pre-
transplant (baseline) and day 0 (post-conditioning) samples iden-
tified different gene sets in PB and in the skin; predominantly
cytokines and their signaling pathways, such as IL2, IL22BP,
IL3, IL4, IL5, IL7, IFNa, EPO, STAT3, ERK5, MAPK, in the
former, and apoptosis, cell cycle and growth (FAS, CDK4,
CDK6, CDKN1B, CDKN2C) in the latter. Gene set enrichment
analysis from day 0 to day +14-21 (engraftment) showed a higher
range of changes in PB (mainly cytokines and immunology gene
sets) than in the skin, which at this point included additional
gene sets from pathways from extracellular matrix and integrins.
This is the first report on a prospective and sequential examina-
tion of gene expression in paired PB and skin samples from
allogeneic BMT recipients. Our results suggest that the pathways
triggered after conditioning therapy and early after BMT differ
between PB and the skin. This finding provides novel insight
into the alloreactive phenomena occurring in humans, and bears
important implications for the identification of novel biomarkers
that may be more relevant to predict GVHD in patients’ target
organs.475
EFFECTIVE TREATMENT OF ACUTE GVHD AFTER HAPLOIDENTICAL BMT
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Graft-versus-host disease (GvHD) is a major complication after
allogeneic bone marrow transplantation (BMT). We and others
previously showed that the co-transplantation of large numbers of
donor-derived CD4+CD25+ regulatory T (Treg) cells protects
from lethal GvHD inmurine BMTmodels.We now tested, whether
Treg cells have also therapeutic efficacy. For this purpose, a haploi-
dentical GvHDmodel (BALB/c/CB6F1) was used and, in analogy
to potential clinical applications, donor Treg cells were expanded in
vitro. CD4+CD25highCD62L+ T cells were purified by FACS and
stimulated polyclonally using anti-CD3/CD28-coated beads. Cells
expanded on average 140-fold (627-fold, n 5 5) within 2 wks and
maintained high levels of FoxP3 expression (9662.3%, n 5 5) as
well as potent immunosuppressive activity in vitro. For the induction
of acute GvHDCB6F1 recipients were lethally irradiated and trans-
planted with 2.5x106 BM cells in combination with 5x106 spleno-
cytes. All animals developed severe GvHD by d11, as revealed by
an increase of the GvHD severity score (2.360.4 in GvHD animals
vs. 060 in BM controls, n 5 10-11) and by histological analyses of
the gut (score: 7.860.4 GvHD group vs. 0.260.2 BM controls,
p 5 0.046, n 5 3). When animals with acute GvHD were treated
with 5x106 in vitro expanded Treg cells on d11 after BMT, treated
and non-treated animals initially showed an identical increase of
their GvHD score. However, from d40 onwards the GvHD score
of mice that had received Treg cells decreased (4.160.6 vs. 6.060
in treated vs. non-treated mice, respectively, on d44, p 5 0.02) and
60% of these mice survived for 100d while all non-treated animals
died by d60 after BMT (p 5 0.014, n 5 10). Successfully treated
mice showed only mild histological signs of gut GvHD on d100 as
compared to non-treated animals with end-stage disease (score:
4.361 vs. 12.560.6 in treated vs. non-treated animals, p 5 0.006,
n5 4-6).Taken together, these results suggest that in vitro expanded
natural Treg cells may not only be effective for the prevention of
acute GvHD, but also for the treatment of acute gastrointestinal
GvHD after allogeneic BMT.476
A PILOT STUDY OF ONCE-DAILY MODIFIED RELEASE FORMULATION
TACROLIMUS HYDRATE (GRACEPTOR) AND PHARMACOKINETIC
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Background:Graceptor is a once-daily modified release formula-
tion of tacrolimus. Not only it maintains its efficacy at the similar
level with the existing drug, Prograf, but also the once-daily ad-
ministration possibly contributes to reduce physical and mental
stress for patients. We investigated the efficacy and safety of the
once-daily administration of tacrolimus in patients who received
allogeneic hematopoietic stem cell transplant recipients from unre-
lated donors (UD-HSCT).
Methods: Patients received tacrolimus 0.03mg/kg intravenous by
continuous infusion, and administration was converted to oral at
a 1:3 or 4 ratios when the patient could tolerate oral medication.
Doses were modified to maintain whole-blood trough levels of
5-10 ng/ml. To analyze pharmacokinetics (PK) of tacrolimus.
Plasma concentration of tacrolimus was determined by ELISA.
Results: A total of 15 patients with hematological malignancies
(AML 6, ALL 3, MDS 3, CML 1, NHL 2) were enrolled. Median
age was 45 (23-65) years. Preparative regimens were myeloablative
(n5 8) or reduced intensity (n5 7), stem cell sources were bonemar-
row (BM) from HLA-matched unrelated donor (n 5 9), BM from
HLA DRB1 mismatched unrelated donor (n 5 2), or cord blood
(n5 4). Three out of 15 patients (20%) developed grade II-IV acute
GVHD, and 3 of 15 patients (20%) developed chronic GVHD. No
